inqovi

Inqovi is an orally administered, fixed-dose combination drug containing decitabine (a nucleoside metabolic inhibitor) and cedazuridine (a cytidine deaminase inhibitor). Decitabine acts as a DNA hypomethylating agent, inhibiting DNA methyltransferase to induce hypomethylation of DNA, which can restore normal function to genes critical for cell differentiation and proliferation. Cedazuridine inhibits cytidine deaminase in the gut and liver, preventing the rapid degradation of decitabine and enabling effective oral administration. Inqovi is primarily indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated or untreated, de novo or secondary MDS with French-American-British subtypes such as refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, chronic myelomonocytic leukemia (CMML), and intermediate-1/2 or high-risk International Prognostic Scoring System groups. It was first approved by the FDA on July 7, 2020[3][4][5][6][8].

Brand names

Inqovi

Other names

decitabine and cedazuridine